第一金融网主办
»您现在的位置: 第一金融网 >> 财经金融 >> 文传商讯 >> 正文

Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio

2019/10/8 14:40:24  文章来源:文传商讯  作者:文传商讯
文章简介: PARIS--(BUSINESSWIRE)--Servier,anindependentinternationalpharmaceuticalcompany,todayannouncedtheacquisitionofPIXUVRI®fromCTIBioPh

PARIS--(BUSINESS WIRE)--Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.

“The acquisition of PIXUVRI is an important step towards Servier’s long-term strategy to become a key player in oncology. Within oncology, one of our key focuses is hematology, and we now have two medicines that are marketed globally alongside a strong and innovative pipeline of drug candidates which includes CAR-T therapies,” said Claude Bertrand, Executive VP, Global Head of R&D at Servier. “As part of our strategy, we are committed to invest 50% of our R&D budget in oncology.”

Non-Hodgkin lymphoma (NHL) is a blood cancer that affects the lymphatic system, it can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.1 Globally there are over 500,000 new cases of NHL a year; it is both the 11th most commonly diagnosed cancer and cause of cancer death.2

“We have a strong commitment to providing effective solutions for patients living with cancer. PIXUVRI is an effective treatment that received standard European marketing authorization in June, and today marks a new step towards achieving Servier’s long term goals. We will ensure that patients will continue to have access to PIXUVRI”, said Eric Falcand, VP, Global Head of Business Development & Licensing at Servier. “We are continuing to strengthen our oncology portfolio through our R&D efforts and strategic alliances.”

#ENDS#

About PIXUVRI (pixantrone)

PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.3 PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.3 PIXUVRI is also approved in Iceland, Israel, Liechtenstein, Myanmar, Norway, Pakistan, Russia and Ukraine.

PIXUVRI is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.4

More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics and immune targeted therapies, to deliver life-changing medicines to patients.

More information: www.servier.com

Follow us on Social Media: LinkedIn I Facebook I Twitter


1 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma. Last accessed September 2019.
2 World Health Organisation. Globocan 2018. Non-Hodgkin lymphoma. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkin-lymphoma-fact-sheet.pdf. Last accessed September 2019.
3 European Medicines Agency. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf. Last accessed September 2019.
4 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at: http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma. Last accessed September 2019.

分享到:
第一金融网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  我和我的祖国70周年国庆节手抄报内容资料素材大
     国庆节主题手抄报模板大全:建国70周年国庆节手
    [银行]  2019银行概念股票一览?财政部新规引发银行股飘
     2019银行从业资格证报名时间 报名需要什么条件?
    [股票]  我国又发现10亿吨级大油田 中国石油市值大增超2
     十亿吨级大油田被发现 四川盆地超万亿方页岩气区
    [基金]  200余家上市公司获真金白银增持 有你的票吗?
     基民"嗨了"!这20只基金狂赚70%以上,前三季度冠
    [保险]  人保车险理赔时间规定
     职工医保和新农合医保哪个好?主要看这三点
    [期货]  国庆节后国内油价或迎“三连涨”
     原油暴涨暴跌波及化工产业 去年苯乙烯价差超600
    [股评]  下周二最具爆发力六大黑马(10/8)
     六大券商下周二看好六大板块(10/8)
    [港股]  港股通中秋休市安排2019:开市时间9月16日起
     阿里20亿美元全资收购网易考拉并领投网易云音乐
    [美股]  百度卖携程股份,价值十亿美元
     WeWorkceo离职怎么回事?还拟裁员5000!WeWork还
    [外汇]  华尔街突遭“美元荒” 本周重点关注欧美制造业P
     17日人民币对美元汇率中间价下调73个基点
    [债券]  2019国庆假期国债逆回购时间表 让你小长假躺着赚
     中国10年国债收益率 今年波幅七年来最小
    [黄金]  2020庚子鼠年贺岁银条哪里预约?怎么购买?
     中国为何不把存美国黄金运回?因为美国不敢私吞
    [理财]  微信支付宝绑定银行卡的 赶紧删了手机里这些照片
     组图:网友前置摄像头跟拍那英 疑似惹对方不满遭
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [房产]  楼市调控坚持“房住不炒” “金九银十”或成色不
     陕西秦岭保护再升级:违建最高罚两百万
    [汽车]  4年亏损220亿,蔚来迎战艰难时刻
     10月25日上市! 丰田全新RAV4配多种动力系统
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版权所有·第一金融网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一金融网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一金融网无关!股市有风险,投资需谨慎。

    合作邮箱:fengyueyoubian@sina.com 合作电话:18678839953 点击这里给我发消息